Diagnosis requires a combination of clinical performance, imaging, laboratory testing, and pathological evaluation. The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnoses and treatment plans. Treatment plans for treatment and management of congenital non-nuclear platelets require individual development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and multi-dimensional management.
In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, with timely adjustment according to the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of the reduction of congenital non-nuclear cell platelets.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.